Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Jun;32(6):E1-6.
doi: 10.1002/clc.20295.

Carbon-coated stents in patients with acute coronary syndromes

Affiliations

Carbon-coated stents in patients with acute coronary syndromes

Jochen Wöhrle et al. Clin Cardiol. 2009 Jun.

Abstract

Background: For patients with ST elevation myocardial infarction (STEMI) or non-ST elevation myocardial infarction (NSTEMI), rapid restoration of coronary blood flow is the primary therapeutic goal. Because of the acute nature of this clinical presentation, bleeding risks may not be adequately evaluated, limiting the use of drug-eluting stents, since premature discontinuation of antiplatelet therapy strongly predicts stent thrombosis. We evaluated angiographic and clinical results of non-drug-eluting carbon-coated stents.

Methods: In this prospective observational study, angiographic and clinical 6-mo results of a carbon-coated stent for treatment of acute lesions in native coronary arteries were evaluated. Angiographic main outcome measures included in-stent late loss and binary restenosis rate. Major adverse cardiac events (MACEs) were defined as any death, Q-wave myocardial infarction (MI), and target lesion revascularization.

Results: We included 320 patients with STEMI (n = 205) or NSTEMI (n = 115) with 360 lesions. Reference vessel diameter was 2.93 +/- 0.53 mm and stented length 22.7 +/- 13.8 mm. Angiographic follow-up was available in 220 of 360 lesions (61%). In-stent late loss was 0.69 +/- 0.75 mm, with a binary restenosis rate of 19.1%. For the total segment late loss was 0.74 +/- 0.77 mm and binary restenosis rate 21.4%. Clinical follow-up for 97.4% of discharged patients was available. Hierarchical MACEs were death in 14 patients (4.4%), Q-wave MI in 3 patients (0.9%), and target lesion revascularization in 39 patients (12.2%).

Conclusion: In this prospective, observational study, the use of a carbon-coated stent for treatment of lesions in patients with STEMI or NSTEMI was associated with a low late loss, translating into a low binary angiographic restenosis rate within a 6-mo follow-up.

PubMed Disclaimer

Similar articles

Cited by

  • In Vitro Biodegradation of a-C:H:SiOx Films on Ti-6Al-4V Alloy.
    Grenadyorov A, Solovyev A, Oskomov K, Porokhova E, Brazovskii K, Gorokhova A, Nasibov T, Litvinova L, Khlusov I. Grenadyorov A, et al. Materials (Basel). 2022 Jun 15;15(12):4239. doi: 10.3390/ma15124239. Materials (Basel). 2022. PMID: 35744297 Free PMC article.

References

    1. Laarman GJ, Suttorp MJ, Dirksen MT, van Heerebeek L, Kiemeneij F, et al.: Paclitaxel‐eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med 2006; 355: 1105–1113. - PubMed
    1. Spaulding C, Henry P, Teiger E, Beatt K, Bramucci E, et al.: Sirolimus‐eluting versus uncoated stents in acute myocardial infarction. N Engl J Med 2006; 355: 1093–1104. - PubMed
    1. Lagerqvist B, James SK, Stenestrand U, Lindback J, Nilsson T, et al.: Long‐term outcomes with drug‐eluting stents versus bare‐metal stents in Sweden. N Engl J Med 2007; 356: 1009–1019. - PubMed
    1. Nordmann AJ, Briel M, Bucher HC: Mortality in randomized controlled trials comparing drug‐eluting vs. bare metal stents in coronary artery disease: a meta‐analysis. Eur Heart J 2006; 27: 2784–2814. - PubMed
    1. Park DW, Park SW, Park KH, Lee BK, Kim YH, et al.: Frequency of and risk factors for stent thrombosis after drug‐eluting stent implantation during long‐term follow‐up. Am J Cardiol 2006; 98: 352–356. - PubMed

MeSH terms